Show simple item record

dc.contributor.authorGiovinazzo, D
dc.contributor.authorBursac, B
dc.contributor.authorSbodio, JI
dc.contributor.authorNalluru, S
dc.contributor.authorVignane, T
dc.contributor.authorSnowman, AM
dc.contributor.authorAlbacarys, LM
dc.contributor.authorSedlak, TW
dc.contributor.authorTorregrossa, R
dc.contributor.authorWhiteman, M
dc.contributor.authorFilipovic, MR
dc.contributor.authorSnyder, SH
dc.contributor.authorPaul, BD
dc.date.accessioned2021-03-15T14:25:27Z
dc.date.issued2021-01-26
dc.description.abstractAlzheimer’s disease (AD), the most common cause of dementia and neurodegeneration in the elderly, is characterized by deterioration of memory and executive and motor functions. Neuropathologic hallmarks of AD include neurofibrillary tangles (NFTs), paired helical filaments, and amyloid plaques. Mutations in the microtubule-associated protein Tau, a major component of the NFTs, cause its hyperphosphorylation in AD. We have shown that signaling by the gaseous molecule hydrogen sulfide (H2S) is dysregulated during aging. H2S signals via a posttranslational modification termed sulfhydration/persulfidation, which participates in diverse cellular processes. Here we show that cystathionine γ-lyase (CSE), the biosynthetic enzyme for H2S, binds wild type Tau, which enhances its catalytic activity. By contrast, CSE fails to bind Tau P301L, a mutant that is present in the 3xTg-AD mouse model of AD. We further show that CSE is depleted in 3xTg-AD mice as well as in human AD brains, and that H2S prevents hyperphosphorylation of Tau by sulfhydrating its kinase, glycogen synthase kinase 3β (GSK3β). Finally, we demonstrate that sulfhydration is diminished in AD, while administering the H2S donor sodium GYY4137 (NaGYY) to 3xTg-AD mice ameliorates motor and cognitive deficits in AD.en_GB
dc.description.sponsorshipUS Public Health Service Granten_GB
dc.description.sponsorshipAmerican Heart Association (AHA)–Allen Initiative in Brain Health and Cognitive Impairmenten_GB
dc.description.sponsorshipMedical Research Council (MRC)en_GB
dc.description.sponsorshipEuropean Union Horizon 2020en_GB
dc.identifier.citationVol. 118 (4), article e2017225118en_GB
dc.identifier.doi10.1073/pnas.2017225118
dc.identifier.grantnumberDA044123en_GB
dc.identifier.grantnumberMR/S002626/1en_GB
dc.identifier.grantnumber864921en_GB
dc.identifier.urihttp://hdl.handle.net/10871/125133
dc.language.isoenen_GB
dc.publisherNational Academy of Sciencesen_GB
dc.rights.embargoreasonUnder embargo until 26 July 2021 in compliance with publisher policyen_GB
dc.rights© 2021 National Academy of Sciences. All rights reserved.en_GB
dc.subjectAlzheimer’s diseaseen_GB
dc.subjectHydrogen sulfideen_GB
dc.subjectTauen_GB
dc.subjectSulfhydrationen_GB
dc.subjectPersulfidationen_GB
dc.subjectCystathionine γ-lyaseen_GB
dc.subjectNaGYYen_GB
dc.subjectGSK3betaen_GB
dc.titleHydrogen sulfide is neuroprotective in Alzheimer’s disease by sulfhydrating GSK3β and inhibiting Tau hyperphosphorylationen_GB
dc.typeArticleen_GB
dc.date.available2021-03-15T14:25:27Z
dc.identifier.issn0027-8424
dc.descriptionThis is the author accepted manuscript. The final version is available from the National Academy of Sciences via the DOI in this recorden_GB
dc.descriptionData Availability. All study data are included in the article and supporting information.en_GB
dc.identifier.journalProceedings of the National Academy of Sciencesen_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2021-01-26
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-03-15T14:20:21Z
refterms.versionFCDAM
refterms.dateFOA2021-07-25T23:00:00Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record